{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-091959","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.372168+00:00","generated_at":"2026-05-30T08:10:45.818819+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics","bullets":["Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.","Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.","Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.","Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.","Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-091959","json":"https://secwatch.observer/filing/0001213900-24-091959.json","markdown":"https://secwatch.observer/filing/0001213900-24-091959.md","text":"https://secwatch.observer/filing/0001213900-24-091959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/0001213900-24-091959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/ea0219021-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:10:45.818819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}